ImmunityBio Inc [NASDAQ: IBRX] stock went on a downward path that fall over -3.76% on Friday, amounting to a one-week price decrease of less than -2.54%.
Over the last 12 months, IBRX stock dropped by -48.49%. The one-year ImmunityBio Inc stock forecast points to a potential upside of 73.07. The average equity rating for IBRX stock is currently 1.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $2.71 billion, with 853.39 million shares outstanding and 91.82 million shares in the current float. Compared to the average trading volume of 8.85M shares, IBRX stock reached a trading volume of 16698700 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on ImmunityBio Inc [IBRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IBRX shares is $11.40 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IBRX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for ImmunityBio Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on May 20, 2025. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on March 06, 2025, representing the official price target for ImmunityBio Inc stock. Previously, the target price had yet another raise to $6, while BTIG Research analysts kept a Buy rating on IBRX stock. On May 12, 2023, analysts decreased their price target for IBRX shares from 10 to 4.
The Average True Range (ATR) for ImmunityBio Inc is set at 0.25, with the Price to Sales ratio for IBRX stock in the period of the last 12 months amounting to 86.79.
IBRX Stock Performance Analysis:
ImmunityBio Inc [IBRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.54. With this latest performance, IBRX shares gained by 23.29% in over the last four-week period, additionally sinking by -33.84% over the last 6 months – not to mention a drop of -48.49% in the past year of trading.
#####
Insight into ImmunityBio Inc Fundamentals:
ImmunityBio Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.05 and a Current Ratio set at 2.22.
ImmunityBio Inc [IBRX] Institutonal Ownership Details
The top three institutional holders of IBRX stocks are: VANGUARD GROUP INC with ownership of 13.83 million shares, which is approximately 2.0135%. BLACKROCK INC., holding 11.42 million shares of the stock with an approximate value of $$72.19 million in IBRX stocks shares; and BLACKROCK INC., currently with $$49.7 million in IBRX stock with ownership which is approximately 1.1448%.
